Nergis DUZOK, Kiper ASLAN, Bahadir KOSAN, Işıl KASAPOĞLU, Gürkan UNCU

Büyüme hormonu seviyeleri ile over rezervleri arasındaki ilişki

Amaç: Bu çalışmanın amacı düşük over rezervi ve açıklanamayan infertilite sebebi ile in-vitro fertilizasyon uygulanacak hastalarda serum Anti-Mulleryen hormon seviyeleri ile büyüme hormonu seviyeleri arasındaki ilişkiyi araştırmaktır. Gereç ve Yöntem: Bu prospektif kohort çalışması 154 kadını içermektedir. Kadınlar üç ana grup altında incelenmiştir. Grup 1; düşük over rezervi (DOR) nedeni ile, Grup-2 ise açıklanamayan infertilite nedeni ile IVF-ICSI (in vitro fertilizasyon, intrasitoplazmik sperm enjeksiyonu) tedavisi uygulanan kadınlardan, Grup-3 ise sağlıklı kadınlardan oluşmaktadır. Hasta verileri prospektif olarak kaydedilmiş olup, yaş vücut kitle indeksi, antral folikül sayısı, gravida, parite, eğitim, meslek, sigara ve alkol kullanımı ve laboratuvar sonuçları (anti-mullerian hormon (AMH), Büyüme hormonu (GH), folikül sitmulan hormon, luteinizan hormon ve estradiol). Bulgular: 154 kadından oluşan çalışma popülasyonu; Grup-1 de 52, Grup-2 de 52 ve Grup-3 de 50 kadın olmak üzere gruplandırılmıştır. Ortalama kadın yaşı Grup-1 de diğer iki gruba göre daha yüksek bulunmuştur (Sırasıyla, medyan ve çeyrek değerleri ile, 35.5 (25-40), 29.5 (20-38), 33 (19-39). Diğer demografik veriler her üç grup arasında benzer bulunurken, serum AMH medyan değerleri Grup-1 de daha düşük bulunmuş ancak büyüme hormon seviyeleri üç grup arasında benzer olarak saptanmıştır. Sonuç: Bu çalışma, serum büyüme hormonu ve over rezerv belirteçleri arasında herhangi bir korelasyon olmadığını göstermiştir. Her ne kadar over rezervi ile GH arasında korelasyon gözlenmese de büyüme hormonunun granuloza hücre fonksiyonlarında önemli rolü olduğu unutulmamalıdır.

Anahtar Kelimeler:

Anti-Mülleryen Hormon, Büyüme Hormonu, Yumurtalık Rezervi, İnfertilite

Relationship between growth hormone levels and ovarian reserves

Purpose: The aim of this study was to investigate the relationship between serum anti mullerian hormone levels and serum growth hormone levels in patients with diminished ovarian reserve and unexplained infertility who are planned for in vitro fertilization. Materials and Methods: This prospective cohort study includes 154 women and comprises three study groups which include infertile women with diminished ovarian reserve (Group I), women with unexplained infertility (Group II) and healthy women (Group III) as control group. Prospectively recorded patient data comprehended age, body mass index (BMI), antral follicle count (AFC), gravidity and parity, education, occupation, smoking and alcohol use, and laboratory results (Anti-Mullerian hormone (AMH), Growth Hormone (GH), Follicle-Stimulating hormone, Luteinizing Hormone and Estradiol). Results: The study population consisted of 154 subjects, 52 in Group-I, 52 in Group-II, and 50 in Group-III. The mean women age was higher in DOR group than the other two groups (Respectively with quartiles; 35.5(25-40), 29.5(20-38), 33(19-39)). The other demographic parameters were similar between the groups. Median serum AMH levels was lower in DOR group. Growth hormone levels were similar between the groups.. Conclusion: Our results show that growth hormone has no relationship between ovarian reserve markers. Although lack of relation with ovarian reserve, it’s widely known that GH plays major role in granulosa cell function.

Keywords:

Growth Hormone Diminished Ovarian Reserve, Anti-Mullerian Hormone, İnfertility, Ovarian Function,

PDF

___

1. Practice Committee of the American Society for Reproductive Medicine. Definitions of infertility and recurrent pregnancy loss. Fertil Steril. 2013;99:63.
2. Maroulis GB. Effect of aging on fertility and pregnancy. Semin Reprod Endocrinol. 1991;9:165-75.
3. Hugh S. Taylor, Pal L, Seli E (editors) Ovarian reserve and its assessment. Speroff's Clinical Gynecologic Endocrinology and Fertility. 9th Edition., Philadelphia: Lippincott Williams & Wilkins, 2019,p.2543-51.
4. Weenen C, Laven JS, Von Bergh AR. Anti-Mullerian hormone expression pattern in the human ovary: potential implications for initial and cyclic follicle recruitment. Mol Hum Reprod. 2004;10:77-83.
5. Durlinger AL, Visser JA, Themmen APN. Regulation of ovarian function: the role of anti-müllerian hormone. Reproduction. 2002;124:601-9.
6. Muttukrishna S, McGarrigle H, Wakim R. Antral follicle count, antimullerian hormone and inhibin B: predictors of ovarian response in assisted reproductive technology? Br J Obstet Gynaecol. 2005;112:1384-90.
7. Van Rooij IA, Broekmans FJ, te Velde ER. Serum anti-mullerian hormone levels: a novel measure of ovarian reserve. Hum Reprod. 2002;17:3065-71.
8. Ebner T, Sommergruber M, Moser M. Basal level of anti-mullerian hormone is associated with oocyte quality in stimulated cycles. Hum Reprod. 2006;21:2022-6.
9. Hsu CJ, Hammond JM. Concomitant effects of growth hormone on secretion of insulin-like growth factor I and progesterone by cultured porcine granulosa cells. Endocrinology. 1987;121:1343-8.
10. Zhou P, Baumgarten SC, Wu Y. IGF-I signaling is essential for FSH stimulation of AKT and steroidogenic genes in granulosa cells. Mol Endocrinol. 2013;27:511–23.
11. Flaws JA, Hirshfield AN, Hewitt JA. Effect of bcl-2 on the primordial follicle endowment in the mouse ovary. Biol Reprod. 2001;64:1153-9.
12. Choi Y, Rajkovic A. Genetics of early mammalian folliculogenesis. Cell Mol Life Sci. 2006;63:579-90.
13. Hsueh AJ, Eisenhauer K, Chun SY. Gonadal cell apoptosis. Recent Prog Horm Res. 1996;51:433–56.
14. Bassiouny YA, Dakhly DMR, Bayoumi YA. Does the addition of growth hormone to the in vitro fertilization/intracytoplasmic sperm injection antagonist protocol improve outcomes in poor responders? A randomized, controlled trial. Fertil Steril. 2016;105:697–702.
15. Bayoumi YA, Dakhly DM, Bassiouny YA. Addition of growth hormone to the microflare stimulation protocol among women with poor ovarian response. Int J Gynaecol Obstet. 2015;131:305–8.
16. Eftekhar M, Aflatoonian A, Mohammadian F. Adjuvant growth hormone therapy in antagonist protocol in poor responders undergoing assisted reproductive technology. Arch Gynecol Obstet. 2013;287:1017–21.
17. Lattes K, Brassesco M, Gomez M. Low-dose growth hormone supplementation increases clinical pregnancy rate in poor responders undergoing in vitro fertilisation. Gynecol Endocrinol. 2015;31:565–8.
18. Sood A, Mohiyiddeen G, Ahmad G, Fitzgerald C, Watson A, Mohiyiddeen L. Growth hormone for in vitro fertilisation (IVF). Cochrane Database Syst Rev. 2021;11:CD000099.
19. Cozzolino M, Cecchino GN, Troiano G, Romanelli C. Growth hormone cotreatment for poor responders undergoing in vitro fertilization cycles: a systematic review and meta-analysis. Fertil Steril. 2020;114:97- 109.
20. Esteves SC, Roque M, Bedoschi GM. Defining low prognosis patients undergoing assisted reproductive technology: poseidon criteria—the why. Front. Endocrinol (Lausanne). 2018;9:461.
21. Steiner AZ, Pritchard D, Stanczyk FZ. Association between biomarkers of ovarian reserve and infertility among older women of reproductive age. JAMA. 2017;318:1367-76.
22. Gnoth C, Schuring AN, Friol K. Relevance of antimullerian hormone measurement in a routine IVF program. Hum Reprod. 2008;23:1359-65.
23. Penarrubia J, Fabregues F, Manau D. Basal and stimulation day 5 anti-mullerian hormone serum concentrations as predictors of ovarian response and pregnancy in assisted reproductive technology cycles stimulated with gonadotropin-releasing hormone agonist–gonadotropin treatment. Hum Reprod. 2005;20:915-22.
24. Devesa J, Caicedo D. The role of growth hormone on ovarian functioning and ovarian angiogenesis. Front Endocrinol (Lausanne). 2019;10:450.
25. Møller N, Jorgensen JO. Effects of growth hormone on glucose, lipid, and protein metabolism in human subjects. Endocr Rev. 2009;30:152-77.
26. El-Roeiy A, Chen X, Roberts VJ. Expression of insulin-like growth factor-I (IGF-I) and IGF-II and the IGF-I, IGF-II, and insulin receptor genes and localization of the gene products in the human ovary. J Clin Endocrinol Metab. 1993;77:1411-8.
27. Voutilainen R, Franks S, Mason HD. Expression of insulin-like growth factor (IGF), IGF binding protein, and IGF receptor messenger ribonucleic acids in normal and polycystic ovaries. J Clin Endocrinol Metab. 1996;81:1003-8.
28. Scacchi M, Pincelli AI, Cavagnini F. Growth hormone in obesity. Int J Obes Relat Metab Disord. 1999;23:260-71.
29. Luque RM, Kineman RD. Impact of obesity on the growth hormone axis: evidence for a direct inhibitory effect of hyperinsulinemia on pituitary function. Endocrinology. 2006;147:2754-63.
30. Scheffler F, Vandecandelaere A, Soyez M, Bosquet D, Lefranc E, Copin H et al. Follicular GH and IGF1 levels are associated with oocyte cohort quality: A pilot study. Front Endocrinol (Lausanne). 2021;12:793621.
31. Rabinovici J, Dandekar P, Angle MJ, Rosenthal S, Martin MC. Insulin-like growth factor I (IGF-I) levels in follicular fluid from human preovulatory follicles: correlation with serum IGF-I levels. Fertil Steril. 1990;54:428-33.
32. Artini PG, Battaglia C, D'Ambrogio G, Barreca A, Droghini F, Volpe A et al. Relationship between human oocyte maturity, fertilization and follicular fluid growth factors. Hum Reprod. 1994;9:902-6.
33. Kwon H, Choi DH, Bae JH, Kim JH, Kim YS. mRNA expression pattern of insulin-like growth factor components of granulosa cells and cumulus cells in women with and without polycystic ovary syndrome according to oocyte maturity. Fertil Steril. 2010;94:2417-20.
34. Jimena P, Castilla JA, Peran F, Molina R, Ramirez JP, Acebal M et al. Insulin and insulin-like growth factor I in follicular fluid after induction of ovulation in women undergoing in vitro fertilization. J Reprod Fertil. 1992;96:641-7.
35. Mendoza C, Cremades N, Ruiz-Requena E, Martinez F, Ortega E, Bernabeu S et al. Relationship between fertilization results after intracytoplasmic sperm injection, and intrafollicular steroid, pituitary hormone and cytokine concentrations. Hum Reprod. 1999;14:628-35.
36. Hammond JM, Baranao JL, Skaleris D, Knight AB, Romanus JA, Rechler MM. Production of insulin-like growth factors by ovarian granulosa cells. Endocrinology. 1985;117:2553-5.
37. Gleicher N, Darmon SK, Molinari E, Patrizio P, Barad DH. Importance of IGF-I levels in IVF: potential relevance for growth hormone (GH) supplementation. J Assist Reprod Genet 2022;doi:10.1007/s10815-021-02379-8 (in press).